2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-B0165
    Pravastatin 81093-37-0 98%
    Pravastatin (CS-514) is a competitive HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM.
    Pravastatin
  • HY-B0930
    Efloxate 119-41-5 99.73%
    Efloxate (Angorlisin) is a vasodilator used in the research of chronic coronary insufficiency and angina pectoris. Efloxate binds to Staphylococcus aureus sortase A.
    Efloxate
  • HY-B1304
    (-)-Sparteine sulfate pentahydrate 6160-12-9 98%
    (-)-Sparteine sulfate pentahydrate ((-)-Lupinidine sulfate pentahydrate) is a class 1a antiarrhythmic agent and a sodium channel blocker.
    (-)-Sparteine sulfate pentahydrate
  • HY-B1308
    Adrenalone hydrochloride 62-13-5 99.88%
    Adrenalone hydrochloride is an adrenergic agonist used as a topical vasoconstrictor and hemostatic. Adrenalone hydrochloride is an inhibitor of dopamine β oxidase. Adrenalone hydrochloride is chemically similar to known norepinephrine transporter (NET) ligands with an IC50 of 36.9 μM.
    Adrenalone hydrochloride
  • HY-N0334
    (+)-Magnoflorine 2141-09-5 98%
    (+)-Magnoflorine (α-Magnoflorine) is an orally active aporphine alkaloid with multiple biological activities. (+)-Magnoflorine promotes Parkin/PINK1 -mediated mitochondrial autophagy, inhibits the activation of NLRP3/Caspase-1 pathway, regulates the intestinal microbiota, and exhibits significant anti-inflammatory and immunomodulatory activities. (+)-Magnoflorine inhibits JNK and TLR4/NF-κB signaling pathways, activates Sirt1/AMPK pathway, alleviates neuronal oxidative stress and apoptosis. Magnoflorine upregulates miR-410-3p, inhibits HMGB1/NF-κB pathway, and has anti-tumor activity. (+)-Magnoflorine also has significant antifungal activity.
    (+)-Magnoflorine
  • HY-N2452
    Cochinchinenin C 956103-79-0 98%
    Cochinchinenin C is a GLP-1R agonist that binds to the extracellular domain of the receptor via hydrophobic interactions and hydrogen bonds, and promotes glucose-dependent insulin secretion from pancreatic β-cells. Cochinchinenin C also increases intracellular cAMP and ATP levels. At low concentrations, Cochinchinenin C binds to human serum albumin, alters its microenvironment, and induces dominant static fluorescence quenching. Cochinchinenin C shows almost no cytotoxicity to pancreatic β-cells, and exerts a synergistic effect with Loureirin A (HY-N1505) when binding to human serum albumin. Cochinchinenin C has been widely used in studies of type 2 diabetes, Helicobacter pylori infection, thrombotic diseases, and other conditions.
    Cochinchinenin C
  • HY-Z7721
    (Rac)-Beraprost sodium 88475-69-8 ≥99.0%
    (Rac)-Beraprost ((Rac)-ML 1129) sodium is a racemic isomer of Beraprost sodium (HY-13569A). Beraprost sodium is an orally active prostacyclin analog that inhibits the release of Ca2+ from intracellular storage sites by binding to prostacyclin membrane receptors (Prostaglandin Receptor), leading to relaxation of smooth muscle cells and vasodilation. Beraprost sodium has vasodilatory, antiplatelet, and cytoprotective effects, making it promising for research in the field of cardiovascular diseases, such as thromboangiitis obliterans and atherosclerosis.
    (Rac)-Beraprost sodium
  • HY-101574
    Pratosartan 153804-05-8 99.35%
    Pratosartan is a selective angiotensin II receptor antagonist.
    Pratosartan
  • HY-101610
    OPC-28326 167626-17-7 99.46%
    OPC-28326 is a selective peripheral vasodilator and an angatonist of α2-adrenergic receptor, with Ki of 2040, 285, and 55 nM for α2A-, α2B- and α2C-adrenoceptors, respectively.
    OPC-28326
  • HY-101693
    Senazodan 98326-32-0 98%
    Senazodan (MCI 154) is a Ca2+ sensitiser, and also shows inhibition effect on PDE III.
    Senazodan
  • HY-10274R
    Dabigatran etexilate (Standard) 211915-06-9 98%
    Dabigatran etexilate (Standard) is the analytical standard of Dabigatran etexilate. This product is intended for research and analytical applications. Dabigatran etexilate (BIBR 1048) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation.
    Dabigatran etexilate (Standard)
  • HY-106890
    E4177 135070-05-2 98.82%
    E4177 (57G709) is an orally active angiotensin II receptor antagonist. E4177 can inhibit the growth of vascular smooth muscle cells (HASMC) and the increase of cell surface area. In addition, E4177 can also increase the expression of platelet-derived growth factor (PDGF) receptor. E4177 can be used in the study of vascular diseases.
    E4177
  • HY-108739
    Idarucizumab 1362509-93-0
    Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis.
    Idarucizumab
  • HY-112319
    (R,S)-MK-8457 1312518-84-5 98%
    (R,S)-MK-8457 is a stereoisomer of MK-8457. MK-8457 is a dual inhibitor of Syk and ZAP70.
    (R,S)-MK-8457
  • HY-112998
    Efmoroctocog alfa 1270012-79-7
    Efmoroctocog alfa is a recombinant factor VIII-Fc fusion protein (rFVIIIFc). In mice with hemophilia A, Efmoroctocog alfa provides longer-lasting protection against tail vein transection injury than conventional rFVIII products. In dogs with hemophilia A, Efmoroctocog alfa produces a longer duration of improvement in whole blood clotting time than conventional rFVIII products. Efmoroctocog alfa can be used for research on hemophilia A.
    Efmoroctocog alfa
  • HY-113044
    Uridine 5′-diphosphoglucose 133-89-1 98%
    Uridine 5’-diphosphoglucose (UDP-glucose), secreted by cardiomyocytes during ischemia and reperfu, is a potent agonist of the proinflammatory P2Y14 receptor. It acts an important role in the regulation of inflammation and neutrophil polarization in neutrophils. Uridine 5’-diphosphoglucose is also the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine 5’-diphosphoglucose is promising for research in counteracting myocardial infarction/reperfusion (MIR)-induced inflammation in the heart tissue.
    Uridine 5′-diphosphoglucose
  • HY-113086
    CE(16:1(9Z)) 16711-66-3 99.8%
    CE(16:1(9Z)) (16:1(9Z) CE) is a cholesterol ester. Plasma levels of cholesteryl palmitoleate are increased in ApoE-/- mice exposed to cigarette smoke and in pediatric patients with biliary atresia. Cholesteryl palmitoleate has been used as a standard for the identification of cholesterol esters in human meibomian gland secretions.
    CE(16:1(9Z))
  • HY-113510
    9(S)-HOTrE 89886-42-0 99.9%
    9(S)-HOTrE is a PPARα activator and an inducer of apolipoprotein A-I (apoA-I) mRNA expression. 9(S)-HOTrE upregulates the expression of PPARα target gene CPT1α. 9(S)-HOTrE can be used in the research of cardiovascular diseases.
    9(S)-HOTrE
  • HY-113547
    Nanterinone 102791-47-9 99.87%
    Nanterinone (UK 61260) is a positive inotropic and arterial vasodilating agent. Nanterinone is a phosphodiesterase inhibitor.
    Nanterinone
  • HY-116778
    Prostaglandin G2 51982-36-6 99.9%
    Prostaglandin G2 is a prostaglandin peroxide. Prostaglandin G2 acts as a precursor for thromboxane A2 production, inducing platelet aggregation and serotonin release. Prostaglandin G2 also induces cerebral arteriole injury in anesthetized cats via the generation of reactive oxygen free radicals, triggering persistent vasodilation, reduced reactivity to hypocapnia, and endothelial damage. Prostaglandin G2 can be used in studies related to cerebral arteriole injury.
    Prostaglandin G2
Cat. No. Product Name / Synonyms Application Reactivity